Siemens Healthineers Share Buyback Fails to Halt Stock Decline

Siemens Healthineers shares are experiencing significant downward pressure, trading with notable losses. This decline persists even as the medical technology giant aggressively continues its multi-billion euro share repurchase initiative, creating a situation that is causing uncertainty among investors.

Broad Market Weakness Weighs on Performance

The stock registered a substantial decline of 2.05% in the latest session, dropping to €46.72. This represents a decrease of €0.98 from the previous day’s close. The bearish trend aligns with a broader weakness across the German equity market, where the DAX index concurrently fell by 1.35% to 23,713 points. The prevailing macroeconomic concerns appear to be outweighing the positive impact of company-specific actions.

Uninterrupted Share Repurchase Activity

Despite the falling share price, management is demonstrating its commitment to the buyback program. The initiative, which commenced on March 24, 2025, is being executed as planned. The company’s 23rd interim report, dated September 1, detailed the acquisition of its own shares during the prior trading week from August 25 to August 31.

Should investors sell immediately? Or is it worth buying Siemens Healthineers?

Throughout this period, Siemens Healthineers purchased a total of 154,496 of its own shares. All transactions were executed exclusively via the XETRA trading platform, with the following daily breakdown:

• August 25: 23,839 shares at an average price of €47.6886
• August 26: 20,000 shares at an average price of €47.4407
• August 27: 37,077 shares at an average price of €47.4664
• August 28: 39,260 shares at an average price of €47.3220
• August 29: 34,320 shares at an average price of €47.3567

Since the program’s inception, the company has now repurchased a considerable 5,678,190 shares. However, this substantial volume has so far proven insufficient to sustainably reverse the downward trajectory of the stock, leading investors to question when the buyback will begin to exert its intended supportive effect on the share price.